|
注册号: Registration number: |
ChiCTR2400080340 |
|
最近更新日期: Date of Last Refreshed on: |
2024-01-26 14:44:22 |
|
注册时间: Date of Registration: |
2024-01-26 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于真实世界的安宫降压丸治疗原发性高血压的回顾性队列研究 |
|
Public title: |
A retrospective cohort study on the treatment of primary hypertension with Angong Jiangya Pill based on the real world |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于真实世界的安宫降压丸治疗原发性高血压的回顾性队列研究 |
|
Scientific title: |
A retrospective cohort study on the treatment of primary hypertension with Angong Jiangya Pill based on the real world |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
靳韬 |
研究负责人: |
唐启盛 |
|
Applicant: |
Jin Tao |
Study leader: |
Tang Qisheng |
|
申请注册联系人电话: Applicant telephone: |
+86 153 1189 5106 |
研究负责人电话:
Study leader's |
+86 10 5207 5438 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
33091694@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
tangqisheng@263.net |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市丰台区南三环东路23号1号楼8层中段办公801 |
研究负责人通讯地址: |
北京市朝阳区安外小关街51号 |
|
Applicant address: |
Room 801, Middle Section, 8th Floor, Building 1, No. 23 South Third Ring East Road, Fengtai District, Beijing |
Study leader's address: |
No. 51 Xiaoguan Street, Wai Andingmen, Chaoyang District, Beijing, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
北京华康嘉合科技有限公司 |
||
|
Applicant's institution: |
Beijing Huakang Jiahe Technology Co., Ltd |
||
|
研究负责人所在单位: |
北京中医药大学第三附属医院 |
||
|
Affiliation of the Leader: |
The Third Affiliated Hospital of Beijing University of Traditional Chinese Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
BZYSY-2024KYKTPJ-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
北京中医药大学第三附属医院科研伦理委员会 |
||
|
Name of the ethic committee: |
Research Ethics Committee of the Third Affiliated Hospital of Beijing University of Traditional Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-01-16 00:00:00 | ||
|
伦理委员会联系人: |
赵莹 |
||
|
Contact Name of the ethic committee: |
Zhao Ying |
||
|
伦理委员会联系地址: |
北京市朝阳区安定门外小关街51号 |
||
|
Contact Address of the ethic committee: |
No. 51 Xiaoguan Street, Wai Andingmen, Chaoyang District, Beijing, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 8498 5602 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
北京中医药大学第三附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Third Affiliated Hospital of Beijing University of Traditional Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市朝阳区安外小关街51号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 51 Xiaoguan Street, Wai Andingmen, Chaoyang District, Beijing, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
北京同仁堂股份有限公司科学研究所 |
||||||||||||||||||||||
|
Source(s) of funding: |
Beijing Tongrentang Co., Ltd. Scientific Research Institute |
||||||||||||||||||||||
|
研究疾病: |
原发性高血压 |
||||||||||||||||||||||
|
Target disease: |
primary hypertension |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||
|
Study phase: |
Retrospective study |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
探讨安宫降压丸对原发性高血压患者的临床疗效和安全性。 |
||||||||||||||||||||||
|
Objectives of Study: |
Exploring the clinical efficacy and safety of Angong Jiangya Pill in patients with primary hypertension. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
(1)观察期间服用与安宫降压丸药物作用类似的中成药(如脑立清丸、清脑降压片、牛黄降压丸等); (2)继发性高血压的患者; (3)合并有严重的心、肝、肾等严重原发性疾病; (4)病例资料不全,主要观察指标严重缺失。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) During the observation period, traditional Chinese patent medicines and simple preparations (such as Naoliqing Pill, Qingnao Jiangya Tablet, Niuhuang Jiangya Pill, etc.) with similar effects to Angong Jiangya Pill were taken; (2) Patients with secondary hypertension; (3) Concomitant with severe primary diseases such as heart, liver, and kidney; (4)The case data is incomplete, and the main observation indicators are severely missing. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-11-13 00:00:00至 To 2025-06-12 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-02-19 00:00:00 至 To 2025-01-16 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
None |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
None |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
NONE |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 EDC:壹道科研数据管理平台 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF EDC:Yidao Research Data Management Platform |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |